Written and compiled by Michelle Fabian, MD and Stephen Krieger, MD
Includes additional material by
Margaret M. McCormick, RN, BSN, MSCN
Reviewed by Jack Burks, MD
Edited by Susan Courtney
MSAA’s 2017 edition of the MS Research Update provides important new data on approved and experimental treatments for MS, and is a valuable resource to the entire MS community. Please note that this update gives an overview of the research behind the approved and experimental medications and therapies for the long-term treatment of multiple sclerosis. It does not include information on any symptom-management medications or therapies.
ATL1102 is an oral agent that affects the VLA-4 system, the same molecular mechanism utilized by Tysabri. It does so via a novel mechanism of action, and falls into a class of “antisense oligonucleotides” not previously used in MS. The results of a Phase II trial were published in 201447, noting that ATL1102 decreased the emergence of new active brain lesions as compared with placebo, after only two months of treatment in approximately 70 individuals with RRMS. In 2016, the company announced its intent to run a Phase 2b.
--------------------------------------
In my opinion we should hear about approval for DMD trial and IND from FDA within months end.Sept.
ANP Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
